research use only
Cat.No.S9521
| Related Targets | Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) |
|---|---|
| Other Adenosine Deaminase Inhibitors | Hibifolin |
|
In vitro |
DMSO
: 54 mg/mL
(201.28 mM)
Water : 54 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 268.27 | Formula | C11H16N4O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 53910-25-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | CI-825,Deoxycoformycin | SMILES | C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O | ||
Read more about storage stability stock solution CAS number SMILES
| References |
|---|
(data from https://clinicaltrials.gov, updated on 2026-01-05)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05757310 | RECRUITING | Recurrent Severe Aplastic Anemia; Refractory Severe Aplastic Anemia |
City of Hope Medical Center |
2024-11-15 | PHASE1 |
| NCT03249831 | ACTIVE_NOT_RECRUITING | Sickle Cell Disease; Sickle Cell Disorder; Hemoglobinopathies; Thalassemia; Anemia, Sickle Cell |
City of Hope Medical Center |
2019-01-04 | PHASE1 |
| NCT03663933 | ACTIVE_NOT_RECRUITING | Lymphoproliferative Disorders; Autoimmune Lymphoproliferative; Primary T-cell Immunodeficiency Disorders; Immune System Diseases; Common Variable Immunodeficiency |
National Cancer Institute (NCI) |
2018-09-04 | PHASE2 |
| NCT02105766 | ACTIVE_NOT_RECRUITING | Sickle Cell Disease; Thalassemia; Stem Cell Transplantation; Graft vs Host Disease |
National Heart, Lung, and Blood Institute (NHLBI) |
2014-04-21 | PHASE2 |
| NCT03077542 | ACTIVE_NOT_RECRUITING | Sickle Cell Disease |
National Heart, Lung, and Blood Institute (NHLBI) |
2017-04-06 | PHASE1; PHASE2 |
| NCT01059786 | ACTIVE_NOT_RECRUITING | Hairy Cell Leukemia |
National Cancer Institute (NCI) |
2010-07-01 | PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.